Left ventricular hypertrophy predicts poorer cardiovascular outcome in normotensive normoglycemic patients with rheumatoid arthritis

Introduction Patients with rheumatoid arthritis (RA) develop early changes in left ventricular (LV) geometry and experience cardiovascular events in excess than in the general population. This study was designed to assess prevalence, predictors and prognostic role of LV hypertrophy (LVH) in a selected group of RA patients with normal blood pressure and glycemia who should be at low risk for LVH. Methods We prospectively analyzed 241 normotensive normoglycemic RA patients (mean age 53 ± 12 years, 61% women) involved in a primary prevention program for cardiovascular diseases who were followed‐up for 40 (24‐56) months. LVH was detected by echocardiography and defined as LV mass ≥49.2 g/m 2.7 for men and ≥46.7 g/m 2.7 for women. Primary outcome was a composite of cardiovascular death/hospitalization. Results LVH was detected in 39 patients (16%). Older age (>53 years), greater body mass index (BMI > 25 kg/m 2 ), longer duration of RA disease, anti‐cyclic citrullinated peptide antibody (ACPA) positivity and concentric LV geometry were the variables associated with LVH. During the follow‐up, a cardiovascular event occurred in 12 of 39 (31%) patients with LVH and in 22 of 202 (11%; P < .001) patients without LVH. LVH independently predicted cardiovascular events (hazards ratio 3.28 [95% CI 1.03‐9.20], P = .03) at Cox regression analysis together with C‐reactive protein and ACPA positivity. Conclusions Nearly one‐sixth of normotensive normoglycemic RA patients analyzed in a primary prevention program for cardiovascular diseases has LVH which is associated with obesity and older age, and strongly predicts cardiovascular event in these subjects.